Chardan Capital Initiates Coverage On Vicore Pharma Holding with Buy Rating, Announces Price Target of $15
Benzinga Newsdesk 1 hour ago
Analyst RatingsNewsInitiationPrice Target
Chardan Capital analyst Andreas Argyrides initiates coverage on Vicore Pharma Holding (NASDAQ:VCRE) with a Buy rating and announces Price Target of $15.
Chardan Capital analyst Andreas Argyrides initiates coverage on Vicore Pharma Holding (NASDAQ:VCRE) with a Buy rating and announces Price Target of $15.